Ashok Rattan1*, Erum Khan2 and Debadatta Panigrahi3
1Advisor, Pathkind Labs, Gurgaon, India 2Lecturer, College of Medicine, Ajman University, United Arab Emirates 3Professor, College of Medicine, Ajman University, United Arab Emirates
1Advisor, Pathkind Labs, Gurgaon, India
2Lecturer, College of Medicine, Ajman University, United Arab Emirates
3Professor, College of Medicine, Ajman University, United Arab Emirates
*Corresponding Author: Ashok Rattan, Advisor, Pathkind Labs, Gurgaon, India.
Received: March 02, 2022; Published: March 28, 2022
Though progress has been made in diagnosis and treatment of Tuberculosis, the slow progress has been compromised by the emergence of drug resistance in M tuberculosis. This drug resistance has been found to occur as point mutation in the target gene of the anti-tubercular drug At present over 15 drugs have been found to be clinically useful for treatment of DR-TB. Thirty-two genes are the target for these drugs and need to be examined for the presence of mutation (resistance). Various laboratory tests have been used for this purpose, but the emergence of Next Generation Sequencing appears to offer an opportunity to take sample from freshly growing M tuberculosis and to simultaneously determine the presence of mutations in any of the 32 genes. With a turnaround time of seven working days, NGS offers the best option to select the most appropriate four drugs which are active against the DR TB that the patient harbours.
Keywords:DR TB; NGS
Citation: Ashok Rattan., et al. “Role of Next Generation Sequencing (NGS) in Diagnosis and Personalised Treatment of Drug Resistance Mycobacterium tuberculosis (DR TB)". Acta Scientific Microbiology 5.4 (2022): 166-175.
Copyright: © 2022 Ashok Rattan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.